UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 160

Sortiert nach

Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease

Blood, 2009-05, Vol.113 (21), p.5074-5082

2009

Volltextzugriff (PDF)

First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation

Biology of blood and marrow transplantation, 2012-08, Vol.18 (8), p.1150-1163

2012

Volltextzugriff (PDF)

Early antimicrobial prophylaxis in autologous stem cell transplant recipients: Conventional versus an absolute neutrophil count‐driven approach

Transplant infectious disease, 2021-08, Vol.23 (4), p.e13689-n/a

2021

Volltextzugriff (PDF)

Lymphocyte Subset Recovery Pattern and Incidence of Infectious Disease after Allogeneic Hematopoietic Stem Cell Transplant

Biology of blood and marrow transplantation, 2017-03, Vol.23 (3), p.S171-S171

2017

Volltextzugriff (PDF)

Granulocyte Colony‐Stimulating Factor Mobilizes More Dendritic Cell Subsets Than Granulocyte‐Macrophage Colony‐Stimulating Factor with No Polarization of Dendritic Cell Subsets in Normal Donors

Stem cells (Dayton, Ohio), 2006-07, Vol.24 (7), p.1789-1797

2006

Volltextzugriff (PDF)

Comparison of Short-Term Response and Long-Term Outcomes after Initial Systemic Treatment of Chronic Graft-Versus-Host Disease

Biology of blood and marrow transplantation, 2011, Vol.17 (1), p.124-132

2011

Volltextzugriff (PDF)

Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial

Biology of blood and marrow transplantation, 2018-11, Vol.24 (11), p.2216-2223

2018

Volltextzugriff (PDF)

Once daily busulfan cyclophosphamide is well tolerated and effective as a preparative regimen for allogeneic hematopoietic stem cell transplant

Journal of oncology pharmacy practice, 2012-03, Vol.18 (1), p.17-22

2012

Volltextzugriff (PDF)

Seventy Nine Miles, Two Sites and One Fact Accreditation: Integrating Effective Quality Management Between Two Affiliated but Physically Remote Hematopoietic Cellular Transplantation (HCT) Facilities

Biology of blood and marrow transplantation, 2017-03, Vol.23 (3), p.S445-S445

2017

Volltextzugriff (PDF)

Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation

Biology of blood and marrow transplantation, 2015-11, Vol.21 (11), p.1921-1925

2015

Volltextzugriff (PDF)

Four Days Tbo-Filgrastim Mobilization for Autologous Transplantation Demonstrates Similar CD34+ Yields and Less Use of Plerixafor

Biology of blood and marrow transplantation, 2017-03, Vol.23 (3), p.S406-S407

2017

Volltextzugriff (PDF)

End of Life Issues for AYA Patients Post Allogeneic Hematopoietic Stem Cell Transplants

Biology of blood and marrow transplantation, 2017-03, Vol.23 (3), p.S226-S227

2017

Volltextzugriff (PDF)

Improving Survival Outcomes for Hematopoietic Cellular Transplant (HCT) Recipients

Biology of blood and marrow transplantation, 2017-03, Vol.23 (3), p.S420-S420

2017

Volltextzugriff (PDF)

Open-Label Study to Determine the Feasibility of Ixazomib As Maintenance after Allogeneic Stem Cell Transplant for Multiple Myeloma

Blood, 2017-12, Vol.130, p.5537-5537

2017

Volltextzugriff (PDF)

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)

Blood, 2020-11, Vol.136 (Supplement 1), p.26-27

2020

Volltextzugriff (PDF)

Pharmacoeconomic Analysis and Clinical Outcomes of Staggered PK-Based Busulfan Dosing during Myeloablative Conditioning for Allogeneic Stem Cell Transplant Recipients

Biology of blood and marrow transplantation, 2017-03, Vol.23 (3), p.S269-S270

2017

Volltextzugriff (PDF)

Retrospective Comparative Analysis of Spectra OptiaÂ® MNC and Cmnc Apheresis Collection Protocols

Biology of blood and marrow transplantation, 2017-03, Vol.23 (3), p.S420-S421

2017

Volltextzugriff (PDF)

Outcomes of Autologous Transplants for Patients with Multiple Myeloma and Concurrent Multiple Plasmacytomas

Blood, 2015-12, Vol.126 (23), p.1973-1973

2015

Volltextzugriff (PDF)

Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation

Bone marrow transplantation (Basingstoke), 2010-06, Vol.45 (6), p.1068-1076

2010

Volltextzugriff (PDF)

A Standardized Cell Dose to Optimize Unrelated Donor Peripheral Blood Stem Cell (PBSC) Collections: A Prospective Study between the Sarah Cannon Transplant and Cellular Therapy Network (SCTCTN) and the National Marrow Donor Program (NMDP)

Transplantation and cellular therapy, 2024-02, Vol.30 (2), p.S245-S245

2024

Volltextzugriff (PDF)

Carvykti (cilta-cel) Real World Outcomes across the Sarah Cannon Transplant Cell Therapy Network

Transplantation and cellular therapy, 2024-02, Vol.30 (2), p.S385-S386

2024

Volltextzugriff (PDF)

Effect of Pre Transplant Residual Leukemia on Post Allogeneic Transplant Survival Outcomes for AML Patients with Primary Induction Failure

Biology of blood and marrow transplantation, 2016-03, Vol.22 (3), p.S445-S446

2016

Volltextzugriff (PDF)

Impact of Anti- T Lymphocyte Globulin (ATLG) on Immune Reconstitution in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT): Results From a Prospective Randomized Double Blind Phase 3 Clinical Trial

Biology of blood and marrow transplantation, 2017-03, Vol.23 (3), p.S170-S171

2017

Volltextzugriff (PDF)

Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors

Haematologica (Roma), 2019-04, Vol.104 (4), p.844

2019

Volltextzugriff (PDF)

1 – 25 von 160

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(97)
Mit Volltextzugriff
(153)

Publikationsform

Artikel
(159)
Bücher
(1)

Sprache

Englisch
(160)
Japanisch
(19)

Erscheinungsjahr

n.n

Thema

Science & Technology
(59)
Life Sciences & Biomedicine
(54)
Humans
(49)
Hematology, Oncology And Palliative Medicine
(31)
Hematology
(28)
Biological And Medical Sciences
(25)
Female
(23)
Male
(22)
Medical Sciences
(21)
Middle Aged
(21)
Transplantation
(20)
Immunology
(19)
Adult
(18)
Oncology
(10)
Aged
(9)
Animals
(9)
Hematopoietic Stem Cell Transplantation
(9)
Immunopathology
(9)
Adolescent
(8)
Hematologic And Hematopoietic Diseases
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease

First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation

Early antimicrobial prophylaxis in autologous stem cell transplant recipients: Conventional versus an absolute neutrophil count‐driven approach

Lymphocyte Subset Recovery Pattern and Incidence of Infectious Disease after Allogeneic Hematopoietic Stem Cell Transplant

Granulocyte Colony‐Stimulating Factor Mobilizes More Dendritic Cell Subsets Than Granulocyte‐Macrophage Colony‐Stimulating Factor with No Polarization of Dendritic Cell Subsets in Normal Donors

Comparison of Short-Term Response and Long-Term Outcomes after Initial Systemic Treatment of Chronic Graft-Versus-Host Disease

Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial

Once daily busulfan cyclophosphamide is well tolerated and effective as a preparative regimen for allogeneic hematopoietic stem cell transplant

Seventy Nine Miles, Two Sites and One Fact Accreditation: Integrating Effective Quality Management Between Two Affiliated but Physically Remote Hematopoietic Cellular Transplantation (HCT) Facilities

Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation

Four Days Tbo-Filgrastim Mobilization for Autologous Transplantation Demonstrates Similar CD34+ Yields and Less Use of Plerixafor

End of Life Issues for AYA Patients Post Allogeneic Hematopoietic Stem Cell Transplants

Improving Survival Outcomes for Hematopoietic Cellular Transplant (HCT) Recipients

Open-Label Study to Determine the Feasibility of Ixazomib As Maintenance after Allogeneic Stem Cell Transplant for Multiple Myeloma

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)

Pharmacoeconomic Analysis and Clinical Outcomes of Staggered PK-Based Busulfan Dosing during Myeloablative Conditioning for Allogeneic Stem Cell Transplant Recipients

Retrospective Comparative Analysis of Spectra OptiaÂ® MNC and Cmnc Apheresis Collection Protocols

Outcomes of Autologous Transplants for Patients with Multiple Myeloma and Concurrent Multiple Plasmacytomas

Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation

A Standardized Cell Dose to Optimize Unrelated Donor Peripheral Blood Stem Cell (PBSC) Collections: A Prospective Study between the Sarah Cannon Transplant and Cellular Therapy Network (SCTCTN) and the National Marrow Donor Program (NMDP)

Carvykti (cilta-cel) Real World Outcomes across the Sarah Cannon Transplant Cell Therapy Network

Effect of Pre Transplant Residual Leukemia on Post Allogeneic Transplant Survival Outcomes for AML Patients with Primary Induction Failure

Impact of Anti- T Lymphocyte Globulin (ATLG) on Immune Reconstitution in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT): Results From a Prospective Randomized Double Blind Phase 3 Clinical Trial

Related peripheral blood stem cell donors experience more severe symptoms and less complete recovery at one year compared to unrelated donors

Suchergebnisse filtern